Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $38.32, for a total transaction of $766,400.00. Following the transaction, the executive vice president owned 140,000 shares of the company’s stock, valued at $5,364,800. This trade represents a 12.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Marshall Urist also recently made the following trade(s):

• On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total transaction of $913,526.10.
• On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total transaction of $714,174.30.
• On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The stock was sold at an average price of $39.93, for a total transaction of $931,686.69.
• On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.90, for a total value of $727,855.80.

Royalty Pharma Price Performance

NASDAQ:RPRX traded down $0.07 during trading hours on Wednesday, reaching $38.31. 2,251,085 shares of the company traded hands, compared to its average volume of 4,333,543. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.48 and a quick ratio of 3.48. The firm’s 50-day moving average is $38.21 and its 200-day moving average is $36.68. The stock has a market cap of $22.11 billion, a P/E ratio of 29.02, a P/E/G ratio of 2.03 and a beta of 0.47. Royalty Pharma PLC has a 1-year low of $24.05 and a 1-year high of $41.24.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share for the quarter, topping analysts’ consensus estimates of $1.11 by $0.06. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%.The company had revenue of $609.29 million during the quarter, compared to analysts’ expectations of $765.01 million. Equities research analysts expect that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th were issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date was Friday, November 14th. Royalty Pharma’s dividend payout ratio is 66.67%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Royalty Pharma in a research note on Tuesday, September 30th. They set a “buy” rating and a $42.00 price target on the stock. Morgan Stanley decreased their target price on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Leerink Partners set a $45.00 price target on Royalty Pharma in a report on Thursday, December 11th. Cowen restated a “buy” rating on shares of Royalty Pharma in a report on Thursday, December 11th. Finally, TD Cowen lifted their price objective on Royalty Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $45.60.

Institutional Trading of Royalty Pharma

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Smartleaf Asset Management LLC raised its position in shares of Royalty Pharma by 868.1% in the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 790 shares during the period. USA Financial Formulas purchased a new position in shares of Royalty Pharma in the 2nd quarter worth about $32,000. Financial Consulate Inc. purchased a new position in shares of Royalty Pharma in the 3rd quarter worth about $35,000. Summit Securities Group LLC acquired a new position in shares of Royalty Pharma in the 1st quarter valued at about $36,000. Finally, Larson Financial Group LLC grew its holdings in shares of Royalty Pharma by 31.9% during the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 306 shares during the period. 54.35% of the stock is currently owned by institutional investors and hedge funds.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.